Seizures in inflammatory demyelinating disorders of the central nervous system.

Abstract

BACKGROUND:

Multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) may be associated with acute symptomatic seizures and chronic epilepsy as well. The clinical features of the seizures and/or accompanying epilepsy seen in each disease group may vary. In this study, we aimed to contribute to the existing literature by describing the clinical features of seizures and epilepsy in our demyelinating patient population.

METHODS:

We retrospectively analyzed patients who were followed up in our tertiary referral center neurology demyelinating diseases outpatient clinic between 2019 and 2024. Patients who had at least one seizure before, simultaneously, or after the diagnosis of demyelinating disease were included in the study.

RESULTS:

Among 1735 patients with MS, 40 had experienced at least one epileptic seizure (2.3 %). Thirty patients (1.7 %) had seizures that could not be explained by another factor than MS. When secondary progressive MS (SPMS) and relapsing-remitting MS (RRMS) were compared, the interval between MS-epilepsy diagnosis was longer and seizure recurrence was more in SPMS. However, the prognosis of epilepsy was good in both subtypes. There were 21 patients followed up with antibody-positive neuromyelitis optica spectrum disorder. No patient had a seizure during the follow-up. We identified 56 patients who fulfilled the criteria for MOGAD with high antibody titers. Seizures were observed in three of them (5.4 %). All of them had status epilepticus either at the onset or during the course of the disease.

CONCLUSION:

Even rare, seizures constitute one of the important clinical features of the inflammatory demyelinating disorders of the central nervous system. The pathophysiologic mechanism underlying seizures in MS is still not clear. Seizures may occur through different mechanisms in patients where seizures are the initial symptom or a sign of relapse and those that occur spontaneously during the progressive course of the disease. Prevalence of status epilepticus was common in MOGAD patients. Given the rarity of the seizures in CNS demyelinating disorders, it is difficult the define clinical and pathophysiological characteristics of accompanying seizures and epilepsy. Future studies conducted on large patient groups will contribute to the existing literature.

• Authors: Özdem Ertürk Çetin, İpek Güngör Doğan, Ümit Zanapalioğlu, Feyzullah Yadi, Damla Çetinkaya Tezer, Serkan Demir
• Journal: Multiple sclerosis and related disorders (Mult Scler Relat Disord) Vol. 85 Pg. 105535 (May 2024) ISSN: 2211-0356 [Electronic] Netherlands
• PMID: 38452647 (Publication Type: Journal Article)
• Copyright: Copyright © 2024 Elsevier B.V. All rights reserved.

Topics

• Humans
• Female
• Adult
• Male
• Retrospective Studies
• Middle Aged
• Seizures (etiology)
• Neuromyelitis Optica (complications, physiopathology, epidemiology, immunology, diagnosis)
• Young Adult
• Multiple Sclerosis (complications, epidemiology, diagnosis)
• Epilepsy (etiology, epidemiology)
• Demyelinating Autoimmune Diseases, CNS (immunology, physiopathology, diagnosis)